Anjali Tiku Owens, MD - Contemporary Data, Differentiation, and Decision-Making in Hypertrophic Cardiomyopathy: A Guide to Cardiac Myosin Inhibition for the Managed Care Professional

For the complete activity, including supporting material, please visit https://www.peervoice.com/ZRT860. Presented by Anjali Tiku Owens, MD; Andrew Willeford, PharmD, PhD, BCCP; and Rachel Lavelle, PharmD, BCCP Learning Objectives: Differentiate between obstructive and non-obstructive hypertrophic cardiomyopathy (oHCM and nHCM) based on their pathophysiology and current guideline-directed management strategies; Evaluate the efficacy and safety of cardiac myosin inhibition as monotherapy or first-line therapy for oHCM in comparison to beta-blockade; Compare available cardiac myosin inhibitors (CMIs) based on their pharmacology, trial designs, outcomes, and practicalities of use; Propose evidence-based treatment pathways for individuals with oHCM that promote optimal patient care, clinical outcomes, access to therapy, and overall resource utilization; Assess emerging data and the investigational treatment landscape for nHCM.

Mentioned

topics

• hypertrophic cardiomyopathy
• cardiac myosin inhibition
• obstructive hypertrophic cardiomyopathy
• non-obstructive hypertrophic cardiomyopathy
• beta-blockade
• cardiac myosin inhibitors

persons

• Anjali Tiku Owens
• Andrew Willeford
• Rachel Lavelle

Listen